This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

RH1

Spectrum Pharmaceuticals, Inc.

Drug Names(s): RH1

Description: RH1 is a targeted cytotoxic prodrug that is bioactivated by the enzyme DT-diaphorase (DTD), which is over-expressed in many tumors relative to normal tissue, including lung, colon, breast and liver tumors. Because RH1 is bioactivated in the presence of DTD, it has the potential to provide targted drug delivery to these tumor types while limiting the toxicity to normal tissue.

The drug exhibits a similar mechanism of action to the potent chemotherapeutic agent Mitomycin C, with greater potential activity against cells expressing high DTD and a potentially more favorable safety profile. Mitomycin C is an antibiotic that, when activated, acts as a DNA alkylating agent. This results in mispairing of bases, DNA strand breakage, and cross-linking of complementary strands which prevents DNA synthesis.

Deal Structure: Allos and Spectrum
In April 2012, Spectrum and Allos announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right (CVR). In September 2012, Spectrum completed its acquisition of Allos.


RH1 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug